Pathogenic mechanisms of neurodegeneration based on the phenotypic expression of progressive forms of immune-mediated neurologic disease

Michael C Levin1,2
Sangmin Lee1,2
Lidia A Gardner1,2
Yoojin Shin1
Joshua N Douglas1,3
Chassidy J Groover1,2

1Veterans Administration Medical Center, Memphis, TN, USA; 2Departments of Neurology, Neuroscience, University of Tennessee Health Science Center, Memphis, TN, USA

Abstract: Considering there are no treatments for progressive forms of multiple sclerosis (MS), a comprehensive understanding of the role of neurodegeneration in the pathogenesis of MS should lead to novel therapeutic strategies to treat it. Many studies have implicated viral triggers as a cause of MS, yet no single virus has been exclusively shown to cause MS. Given this, human and animal viral models of MS are used to study its pathogenesis. One example is human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Importantly, HAM/TSP is similar clinically, pathologically, and immunologically to progressive MS. Interestingly, both MS and HAM/TSP patients were found to make antibodies to heterogeneous nuclear ribonucleoprotein (hnRNP) A1, an RNA-binding protein overexpressed in neurons. Anti-hnRNP A1 antibodies reduced neuronal firing and caused neurodegeneration in neuronal cell lines, suggesting the autoantibodies are pathogenic. Further, microarray analyses of neurons exposed to anti-hnRNP A1 antibodies revealed novel pathways of neurodegeneration related to alterations of RNA levels of the spinal paraplegia genes (SPGs). Mutations in SPGs cause hereditary spastic paraparesis, genetic disorders clinically indistinguishable from progressive MS and HAM/TSP. Thus, there is a strong association between involvement of SPGs in neurodegeneration and the clinical phenotype of progressive MS and HAM/TSP patients, who commonly develop spastic paraparesis. Taken together, these data begin to clarify mechanisms of neurodegeneration related to the clinical presentation of patients with chronic immune-mediated neurological disease of the central nervous system, which will give insights into the design of novel therapies to treat these neurological diseases.

Keywords: human T-lymphotropic virus type 1 (HTLV-1), multiple sclerosis, neurodegeneration, heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), autoimmunity, spastic paraparesis, RNA-binding protein

Clinical phenotype of progressive neurodegenerative diseases

Multiple sclerosis (MS) is the most common human demyelinating disease of the central nervous system (CNS), affecting as much as 0.2% of the population in high-prevalence areas.1 MS most frequently affects middle-aged people, and there are an estimated 2 million cases worldwide,1 of which 400,000 are in the United States.2 Initially, two-thirds of patients develop relapsing-remitting MS (RRMS), in which neurological symptoms occur followed by complete or incomplete recovery.3,4 Over time, a significant proportion (up to 90% within 25 years4) of these patients may...
develop neurological deterioration independent of relapses and thus develop “secondary progressive MS” (SPMS). Approximately 15% of people develop primary progressive MS (PPMS), in which neurological symptoms progress over time without relapses. Thus, the majority of patients develop progressive forms of MS during their lifetime. Progression in individual patients is highly variable, and may be related to whether patients have plaques in the brain, spinal cord, or both. Common symptoms of progressive forms of MS include spastic paraparesis, sensory dysfunction including neuropathic pain, and urinary disturbance.

Despite decades of research, the etiology of MS remains elusive. Evidence indicates that exposure to an environmental agent (such as a virus) in a genetically susceptible person results in a series of immunological events that lead to neurological damage. Importantly, a number of hypotheses have attempted to link exposure to environmental agents with stimulation of the immune response, which in turn leads to CNS damage. One example is molecular mimicry. The challenge in studying molecular mimicry in MS is that an infectious agent has not unequivocally been shown to cause it, although data suggest Chlamydia pneumoniae, human herpes virus 6, or Epstein–Barr virus may play a role. To address this, we use human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) as a model to study molecular mimicry in autoimmune diseases of the CNS, which allows for the direct comparison of the infecting agent with host antigens. Importantly, HAM/TSP patients are similar clinically, pathologically, and immunologically to people with progressive MS. In fact, many HAM/TSP patients were initially diagnosed with PPMS.

In addition to HAM/TSP, progressive forms of MS are clinically and pathologically similar to the hereditary spastic paraplegias (HSPs) (Table 1). The HSPs are a clinically and genetically diverse group of diseases, which like progressive MS and HAM/TSP are characterized by spastic paraparesis, urinary symptoms, and posterior column dysfunction. HSPs are caused by mutations in the spinal paraplegia genes (SPGs). The predominant manifestation of “pure or uncomplicated” HSP is spastic paraparesis. Patients with “complicated” HSPs develop spastic paraparesis concurrent with other neurologic abnormalities, such as ataxia, optic atrophy, peripheral neuropathy, retinopathy, and dementia. MS and HAM/TSP patients also exhibit some of these symptoms. Pathologically, progressive MS, HAM/TSP, and HSP are characterized by damage to and neurodegeneration of the long tracts of the CNS, including the corticospinal tracts and posterior column/medial lemniscal sensory system (Table 1).

### Contribution of neurodegeneration to the pathogenesis of immune-mediated neurological diseases

Over the past several years, there has been a major shift in thinking about the pathogenesis of progressive forms of MS. Prevailing hypotheses suggested that progressive disease and disability were related to the location and volume of MS white-matter plaques (the “plaque-centric” viewpoint), and that neurodegeneration was present only in the latter stages of progressive MS. There is now evidence that neurodegeneration is present in all stages of the disease. In addition, neurodegeneration in progressive forms of MS is not related to white-matter plaques or their location, but rather correlates with gray matter and cortical pathology. Brain magnetic resonance imaging data support the concept that gray-matter disease and neurodegeneration is a more sensitive marker of progression than white-matter disease. For example, gray-matter atrophy is increased when comparing SPMS patients to controls. In addition, there was significantly greater gray-matter than white-matter atrophy when comparing SPMS to other forms of MS, and it was gray-matter atrophy that correlated with disability. Pathologically, cortical demyelination has been shown to contribute significantly to the pathogenesis of MS. Inflammatory cells and neurodegeneration are present in all stages of MS. However, the type and quantity of inflammatory...
cells and the extent of neurodegeneration are related to MS subtype. For example, in early forms of MS (acute and RRMS), T cells and B cells predominate and correlate with demyelination (plaque location) and neuronal injury, as detected by amyloid precursor protein (APP) staining. In progressive forms of the disease, the inflammatory response is more diffuse (involving CNS parenchyma and meninges) and immunoglobulin G (IgG)-positive plasma cells predominate. Importantly, B-cell follicle-like structures present in the meninges in SPMS are associated with cortical pathology such as subpial cortical demyelination and atrophy. Also, there is neuronal loss and apoptosis within the motor cortex, particularly in motor pyramidal neurons in layers III and V, which contain the cells of origin of the corticospinal tract. This is particularly relevant, because in progressive MS patients spastic paraparesis predominates and there is a strong clinical correlation between axonal damage and neurological disability related to the long tracts of the CNS. For example, analysis of the corticospinal tract and posterior columns in the spinal cord of MS patients showed a significant reduction of nerve-fiber density independent of cerebral plaque location, which correlated strongly with progression.

The neuropathology of the spinal cord in HAM/TSP closely resembles that seen in progressive forms of MS, and forms the basis for hypotheses related to the pathogenesis of viral-induced, immune-mediated neurological disease. Like MS, the corticospinal tract and posterior columns are preferentially damaged and demonstrate axonal dystrophy and demyelination. In addition, there is increased APP expression indicative of neurodegeneration within the corticospinal tract. In both HAM/TSP and MS, magnetic resonance images show spinal cord atrophy. There is blood–brain barrier breakdown and infiltration of the CNS with inflammatory cells, which localize predominantly to the thoracic spinal cord, where a majority of cells concentrate in the lateral (inclusive of the corticospinal tract) and posterior columns. These areas also correlate with relatively low blood flow within the spinal cord parenchyma. CD4+ and CD8+ T lymphocytes as well as B cells and natural killer cells have been localized to the spinal cord, and their ratios are related to disease chronicity. Some CD8+ cells costained with T cells restricted intracellular antigen 1, a marker of cytotoxic T cells. Importantly, both HTLV-1 tax provirus and RNA were localized to infiltrating T cells in the spinal cord. There is little evidence of direct infection of neural elements with HTLV-1. Thus, data indicate that immune-mediated mechanisms contribute to the pathogenesis of HAM/TSP. For example, HAM/TSP patients make immune responses to a number of viral targets including HTLV-1 tax, env, and gag that separates them from control populations. Immunologically, HAM/TSP patients develop CD8+, human leukocyte antigen (HLA)-2-restricted cytotoxic T lymphocytes (CTLs) specific for tax and CD4+ responses to both tax and env that are thought to contribute to disease. In contrast, other studies suggest that tax-specific CTLs are protective rather than pathogenic. In addition, CTLs to the newly discovered HTLV-1 basic leucine zipper factor appear to have a protective influence for the development of HAM/TSP. Interestingly, CD8+ lymphocytes also play an important role in the pathogenesis of MS. For example, MS patients have elevated cytotoxic responses by interleukin-15-exposed CD8+ lymphocytes and cytotoxic C8+ lymphocytes are present in MS plaques. In HAM/TSP, other inflammatory cells might also contribute to its pathogenesis including natural killer cells and interferon-γ-secreting Foxp3-CD4+CD25+CCR4+ T cells. Interestingly, the HLA class 2 gene HLA-DRB1*0101 increased HTLV-1 viral load (blood and spinal fluid) and elevated HTLV-1 antibody titers were found to increase the risk of HAM/TSP.

Elevated levels of proinflammatory cytokines such as tumor necrosis factor (TNF)-α and interferon-γ are also associated with HAM/TSP, as are interferon-stimulated genes such as STAT1, STAT2, TAP1, and CXCL10. Taken together, these data are closely related pathologically and immunologically to MS, and suggest that immune-mediated mechanisms contribute to the pathogenesis of both MS and HAM/TSP.

Mechanisms of neurodegeneration in MS are similar to other neurodegenerative diseases

The mechanisms underlying neurodegeneration in MS are an area of intense investigation and remain an open question. There is evidence that neurodegeneration might result from lack of trophic support from myelin, abnormal ion- and sodium-channel expression on axons, calcium accumulation in damaged axons, or Wallerian degeneration. Inflammatory cytokines may also play a role. Several studies have shown that mitochondrial injury and associated oxidative damage, production of reactive oxygen species, and induction of apoptosis contribute to axonal injury. Other studies implicate increased energy demands of demyelinating axons and the relative reduction of axonal adenosine triphosphate (ATP) production, which results in a state of “virtual hypoxia.”
Several studies have demonstrated axonal changes in association with increased APP levels. Importantly, APP accumulation develops in the setting of abnormal fast axonal transport and has been shown not only to accumulate in damaged axons in MS brains but is also an early marker of axonopathy related to impaired axonal transport in Alzheimer’s disease. Notably, increased APP expression is also present within the corticospinal tracts of HAM/TSP patients. Abnormal axonal transport results in neurodegeneration in a number of neurodegenerative diseases. This is particularly evident in the HSPs. For example, some HSP genes, such as spinal paraplegia gene 4 (SPG4 – spastin), SPG7 (paraplegin), and SPG20 (spartin), have all been shown to contribute to axonal transport.

In addition to these mechanisms, recent studies have implicated RNA-binding proteins (RBPs) and their function in RNA metabolism (ie, transport, stability, translation) as major contributors to abnormal neuronal function and neurodegeneration in amyotrophic lateral sclerosis, spinal muscle atrophy, and dementia. For example, the RBP TAR DNA-binding protein 43 has been identified as a major contributor to amyotrophic lateral sclerosis and frontotemporal dementia. Also, RNA metabolism related to fragile X mental retardation protein appears to contribute to the pathogenesis of fragile X syndrome and fragile X syndrome-associated tremor/ataxia. Further, patients with paraneoplastic neurologic syndromes develop antibodies to RBPs, such as Hu and Nova. Taken together, these data show that neurodegeneration in MS involves mechanisms that are also present in other neurodegenerative diseases.

Antibodies as contributors to neurodegeneration and the pathogenesis of MS

In addition to T cells, recent studies have emphasized the role of humoral autoimmunity in the pathogenesis of MS. Clinically, intrathecal IgG and oligoclonal bands are a hallmark of MS. Some types of MS show Ig and complement deposition in MS lesions, and some MS patients exhibit a therapeutic response to plasma exchange or B-cell depletion with anti-CD20 antibodies.

The humoral immune response may be particularly important when studying neurodegeneration. For example, patients with progressive disease are more likely to have B-cell follicle-like structures in the cerebral meninges. IgG-containing plasma cells are found in the meninges and throughout the brain in MS patients, and persist in progressive forms of MS when T cells and B cells diminish to control levels. Importantly, studies also show that antibodies to neurons and axons contribute to the pathogenesis of neurodegeneration in MS. In one study, MS patients were found to make antibodies to neurofascin. The autoantibodies reacted to both neurofascin 186 (a neuronal protein located on axons at the nodes of Ranvier) and neurofascin 155, an oligodendrocyte protein. Application of these antibodies to hippocampal slice cultures inhibited axonal conduction. Following induction of experimental allergic encephalomyelitis with myelin oligodendrocyte glycoprotein-specific T cells, the addition of antineurofascin antibodies augmented disease. The antibodies bound to the nodes of Ranvier, resulting in complement deposition and axonal injury. Taken together, these data indicate antibodies that target neuronal antigens are pathogenic.

These data suggest that antibodies to CNS targets other than myelin, such as neurons and axons, may make major contributions to the pathogenesis of MS. For example, studies in MS patients revealed that there were elevated antibodies to the “axolemma-enriched fraction,” neurofilament, and gangliosides. Also, Owens et al tested recombinant monoclonal antibodies derived from the light-variable region sequences of plasma and B-cell clones isolated from the cerebrospinal fluid (CSF) of MS patients for immunoreactivity to myelin antigens. Remarkably, none of the recombinant antibodies reacted with myelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein. These data suggest the myelin compartment may not always be a target for a pathogenic humoral response in MS patients and that other autoantigens might be important. For example, a recent study showed that autoantibodies to the potassium channel KIR4.1, a glial protein, might contribute to the pathogenesis of MS.

A potential role for antibodies to the RBP hnRNP A1 in the pathogenesis of neurodegeneration in MS and HAM/TSP

Data generated in our lab also indicate that antibodies to the nonmyelin compartment, specifically neurons, may contribute to the pathogenesis of MS and HAM/TSP. Initially,
importantly, an HTLV V-1 protein-fragment experiments showed HAM/TSP and MS IgG reacted with an epitope (amino acids [AA] 293-GQYFAKPRNQGG-304, red box), which is contained within the same epitope in M9. Schematic of heterogeneous nuclear ribonucleoprotein (hnRNP) A1 shows the RNA-binding domains (RBDs), the RGG domain, and M9. Overlapping protein-fragment experiments showed HAM/TSP and MS IgG reacted with an epitope (aa 293-GQYFAKPRNQGG-304) that is biologically active and potentially contributory to the pathogenesis of this immune-mediated neurologic disease. specifically, IgG isolated from the serum of MS patients immunoreacted with neurons but not systemic organs. In addition, MS IgG immunoreacted with the identical M9 epitope as the HAM/TSP patients (Figure 1). The sera of all 37 MS patients examined were positive for the M9 epitope. In contrast, normal controls and patients with Alzheimer’s disease (a control for neurodegenerative disease) showed no immunoreactivity. IgG from the CSF of an MS patient also immunoreacted with the M9 epitope. of note, the study group included 49% RRMS, 27% SPMS, and 24% PPMS. Greater than 89% of patients had clinical evidence of corticospinal dysfunction. other groups have confirmed that IgG isolated from the CSF of HAM/TSP and MS patients immunoreacts with hnRNP A1. we then hypothesized that the anti-hnRNP A1-M9 antibodies might contribute to neurodegeneration. to test this hypothesis, we transfected neurons with anti-M9 and control antibodies and examined them for signs of neurodegeneration and changes in gene expression using microarray. in contrast to control neurons, neurons containing the anti-M9 antibodies showed evidence of neurodegeneration, including positive staining with Fluoro Jade C (a fluorescent marker for degenerating neurons) and loss of neuronal processes. Microarray analyses of total RNA extracted from the cells showed that 866 transcripts were significantly altered by the M9-specific antibodies compared to controls. We investigated the functional significance of the gene-expression changes associated with anti-hnRNP A1 M9 antibody transfection of neurons using a dual bioinformatics approach. First, the 866 genes that were significantly altered by the anti-M9 antibodies were functionally classified by Gene Ontology annotation using the Gene Ontology Tree Machine. Remarkably, the anti-M9 antibodies affected almost all aspects of hnRNP A1’s role in nucleocytoplasmic transport and mRNA processing.

Figure 1 Human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and multiple sclerosis (MS) immunoglobulin G (IgG) react with the same epitope in M9. Schematic of heterogeneous nuclear ribonucleoprotein (hnRNP) A1 shows the RNA-binding domains (RBDs), the RGG domain, and M9. Overlapping protein-fragment experiments showed HAM/TSP and MS IgG reacted with an epitope (aa 293-GQYFAKPRNQGG-304, red box), which is contained within the M9 sequence (aa 268–305).
The second bioinformatics approach we utilized relied on a text-mining system that queries Medline abstracts called GeneIndexer (CompuGenomix, Memphis, TN). We used GeneIndexer to identify genes that correlate with the neural systems affected and the clinical symptoms present in progressive MS and HAM/TSP patients. By querying the identical 866 gene set with the clinical terms paraplegia, spastic, weakness, motor, and sensory and comparing them to nonspecific search terms, GeneIndexer identified networks of genes that correlated strongly with neurodegeneration of the neural systems damaged, and the clinical phenotype expressed, by patients with progressive MS and HAM/TSP (Table 2, column 1). Most notably, the SPGs were involved. Following this output, we manually reviewed the manuscripts (identified by GeneIndexer, which were derived from Medline abstracts) related to each of these genes, and categorized them according to their primary functions (unpublished observation) (Table 2). Importantly, these changes in gene expression in neuronal cell lines were confirmed in neurons isolated from the brains of HAM/TSP and progressive MS patients, suggesting the changes found in vitro are clinically and pathologically relevant.

These data suggest a strong association might exist between hnRNP A1 and the SPGs. To prove such an association exists, we tested for molecular interactions between hnRNP A1 and spastin (SPG4). Following immunoprecipitation of neuronal lysates with anti-hnRNP A1 antibodies, we found that spastin protein was bound to hnRNP A1. This interaction was confirmed by immunohistochemistry, which revealed that spastin and hnRNP A1 colocalized within the nuclei of neurons. In separate experiments (Figure 3), we performed immunoprecipitation of neuronal lysates using hnRNP A1 antibodies, and examined the resulting complex for the presence of spastin mRNA. Following immunoprecipitation with anti-hnRNP A1 antibodies, there was enrichment of the spastin mRNA signal indicative of the binding of spastin mRNA to hnRNP A1 (unpublished observation) (Figure 3). In contrast, there was no signal following immunoprecipitation with a nonspecific antibody, confirming the specificity of spastin mRNA binding to hnRNP A1. These experiments confirm a biological interaction between the

<table>
<thead>
<tr>
<th>Gene ontology output: statistically significant functional gene groups related to hnRNP A1 function</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Biologic process:</td>
</tr>
<tr>
<td>Small GTPase mediated signal transduction (20 genes: ( P = 0.00532 ))</td>
</tr>
<tr>
<td>mRNA processing (14 genes: ( P = 0.00870 ))</td>
</tr>
<tr>
<td>II. Molecular function</td>
</tr>
<tr>
<td>Ran GTPase binding (3 genes: ( P = 0.00091 ))</td>
</tr>
<tr>
<td>Small GTPase binding (6 genes: ( P = 0.00971 ))</td>
</tr>
<tr>
<td>Small GTPase regulator activity (12 genes: ( P = 0.00617 ))</td>
</tr>
<tr>
<td>III. Cellular component</td>
</tr>
<tr>
<td>Nucleoplasm (20 genes: ( P = 0.00158 ))</td>
</tr>
<tr>
<td>Nuclear envelope (9 genes: ( P = 0.00656 ))</td>
</tr>
<tr>
<td>Nuclear membrane (7 genes: ( P = 0.00656 ))</td>
</tr>
<tr>
<td>Nuclear membrane part (7 genes: ( P = 0.00544 ))</td>
</tr>
</tbody>
</table>

The second bioinformatics approach we utilized relied on a text-mining system that queries Medline abstracts called GeneIndexer (CompuGenomix, Memphis, TN). We used GeneIndexer to identify genes that correlate with the neural systems affected and the clinical symptoms present in progressive MS and HAM/TSP patients. By querying the identical 866 gene set with the clinical terms paraplegia, spastic, weakness, motor, and sensory and comparing them to nonspecific search terms, GeneIndexer identified networks of genes that correlated strongly with neurodegeneration of the neural systems damaged, and the clinical phenotype expressed, by patients with progressive MS and HAM/TSP (Table 2, column 1). Most notably, the SPGs were involved. Following this output, we manually reviewed the manuscripts (identified by GeneIndexer, which were derived from Medline abstracts) related to each of these genes, and categorized them according to their primary functions (unpublished observation) (Table 2). Importantly, these changes in gene expression in neuronal cell lines were confirmed in neurons isolated from the brains of HAM/TSP and progressive MS patients, suggesting the changes found in vitro are clinically and pathologically relevant.

These data suggest a strong association might exist between hnRNP A1 and the SPGs. To prove such an association exists, we tested for molecular interactions between hnRNP A1 and spastin (SPG4). Following immunoprecipitation of neuronal lysates with anti-hnRNP A1 antibodies, we found that spastin protein was bound to hnRNP A1. This interaction was confirmed by immunohistochemistry, which revealed that spastin and hnRNP A1 colocalized within the nuclei of neurons. In separate experiments (Figure 3), we performed immunoprecipitation of neuronal lysates using hnRNP A1 antibodies, and examined the resulting complex for the presence of spastin mRNA. Following immunoprecipitation with anti-hnRNP A1 antibodies, there was enrichment of the spastin mRNA signal indicative of the binding of spastin mRNA to hnRNP A1 (unpublished observation) (Figure 3). In contrast, there was no signal following immunoprecipitation with a nonspecific antibody, confirming the specificity of spastin mRNA binding to hnRNP A1. These experiments confirm a biological interaction between the

![Gene ontology output: statistically significant functional gene groups related to hnRNP A1 function](image)

**Figure 2** Genes identified by Gene Ontology are directly related to heterogeneous nuclear ribonucleoprotein (hnRNP) A1 function. The gene categories and some individual genes affected by the anti-M9 antibodies are shown in red type. The complete M9 sequence (amino acids [AA] 268–305) is elongated for emphasis and bordered by the black lines within hnRNP A1. Transportin binds the M9 region at AA 263–289, AA 293–304, which are recognized by the multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis immunoglobulin G anti-M9 immune response, are not bound to transportin, and thus are available for antibody binding.**

**Abbreviation:** GTP, guanosine triphosphate.

(Figure 2). The second bioinformatics approach we utilized relied on a text-mining system that queries Medline abstracts called GeneIndexer (CompuGenomix, Memphis, TN). We used GeneIndexer to identify genes that correlate with the neural systems affected and the clinical symptoms present in progressive MS and HAM/TSP patients. By querying the identical 866 gene set with the clinical terms paraplegia, spastic, weakness, motor, and sensory and comparing them to nonspecific search terms, GeneIndexer identified networks of genes that correlated strongly with neurodegeneration of the neural systems damaged, and the clinical phenotype expressed, by patients with progressive MS and HAM/TSP (Table 2, column 1). Most notably, the SPGs were involved. Following this output, we manually reviewed the manuscripts (identified by GeneIndexer, which were derived from Medline abstracts) related to each of these genes, and categorized them according to their primary functions (unpublished observation) (Table 2). Importantly, these changes in gene expression in neuronal cell lines were confirmed in neurons isolated from the brains of HAM/TSP and progressive MS patients, suggesting the changes found in vitro are clinically and pathologically relevant.

These data suggest a strong association might exist between hnRNP A1 and the SPGs. To prove such an association exists, we tested for molecular interactions between hnRNP A1 and spastin (SPG4). Following immunoprecipitation of neuronal lysates with anti-hnRNP A1 antibodies, we found that spastin protein was bound to hnRNP A1. This interaction was confirmed by immunohistochemistry, which revealed that spastin and hnRNP A1 colocalized within the nuclei of neurons. In separate experiments (Figure 3), we performed immunoprecipitation of neuronal lysates using hnRNP A1 antibodies, and examined the resulting complex for the presence of spastin mRNA. Following immunoprecipitation with anti-hnRNP A1 antibodies, there was enrichment of the spastin mRNA signal indicative of the binding of spastin mRNA to hnRNP A1 (unpublished observation) (Figure 3). In contrast, there was no signal following immunoprecipitation with a nonspecific antibody, confirming the specificity of spastin mRNA binding to hnRNP A1. These experiments confirm a biological interaction between the
anti-M9 autoimmune response and neurodegeneration, as suggested by the bioinformatics analyses.11

**A link between autoimmunity and mechanisms of neurodegeneration**

In summary, HAM/TSP and MS patients make antibodies to an epitope contained within the M9 region of hnRNP A1, an RBP that plays a critical role in RNA metabolism.11,130,131 Alterations in RBP function are associated with neurodegeneration.103 Anti-M9 antibodies caused neurodegeneration, loss of neuronal processes, and altered genes related to hnRNP A1 function and mechanisms of neurodegeneration associated with the clinical phenotype of HAM/TSP and progressive MS patients.11 Thus, a link between autoimmunity, clinical phenotype, and neurodegeneration has been identified. M9 is the nuclear export sequence and nuclear localization sequence of hnRNP A1, which is required for the “nonclassical” (transportin-mediated) pathway of nucleocytoplasmic transport.14,127,141,144

This is of particular interest considering that importins and exportins, which are required for “classical” (β-importin-mediated) nucleocytoplasmic transport, play a crucial role in the shuttle of proteins between the nucleus and cytoplasm.14,127,141,144

### Table 2

<table>
<thead>
<tr>
<th>Name</th>
<th>Neuronal Transport</th>
<th>Mitochondria</th>
<th>Ubiquitin Proteosome System/Autophagy</th>
<th>Endosome Lysosome Peroxisome</th>
<th>Myelination</th>
<th>Axonal Integrity</th>
</tr>
</thead>
<tbody>
<tr>
<td>spg 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>spg 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>spg 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>atxn 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sic6a8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pnma1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>usp14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alms1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>creld1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dym</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>surfl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>wbscr20c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cirrin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ulk2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>migl2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sem 4f</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abcd1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>arsd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>asp1 1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dgrc6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>famil3a1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pom1 21c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d41253</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mid2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>psap</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ofd1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pse1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pse2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sqstm1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cud2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>etv1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kif5c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ift20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myt1l</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>neurgrin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nrg1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ifh88</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
role in nerve injury,\textsuperscript{145-148} and recently were shown to contribute to neurodegeneration in MS.\textsuperscript{148,149} Specifically, in neurons exposed to TNF-\(\alpha\), the transcription factor histone deacetylase 1 was transported from the nucleus to the cytoplasm utilizing the \(\beta\)-importin-mediated nucleocytoplasmic transport system, which resulted in neurodegeneration in a model of MS.\textsuperscript{148} Similar findings were observed in experiments involving the transport of hnRNP A1 (unpublished observation) (Figure 4). Interestingly, spastin contains several nuclear export sequences and nuclear localization sequences, and thus is involved in classical (\(\beta\)-importin-mediated) nucleocytoplasmic transport.\textsuperscript{130} Our data indicate a molecular interaction exists between spastin and hnRNP A1 (Figure 5), thus implicating an interaction between classical and nonclassical nucleocytoplasmic transport, which is a novel experimental observation. How might the anti-M9 immune response directed at the nonclassical nucleocytoplasmic transport system alter the classical nucleocytoplasmic transport system? Although this is not yet known, several possibilities exist. Notably, both the nonclassical and classical nucleocytoplasmic transport pathways are tightly regulated and require the binding of RanGTP to a \(\beta\)-karyopherin (transportin for hnRNP A1 and a \(\beta\)-importin for spastin) to function (Figure 2).\textsuperscript{11,119-124,151} Thus, both pathways are regulated by the same system and an interruption in one may affect the other. For example, binding of anti-M9 antibodies to hnRNP A1 might interrupt the finely tuned regulation of RanGTP, thus altering the classical nucleocytoplasmic transport of spastin. Alternatively, anti-M9 antibodies might sterically hinder hnRNP A1’s binding to spastin protein. Finally, considering our data showing that spastin RNA binds hnRNP A1, anti-M9 antibodies might interfere with spastin’s transport and subsequent translation or localization to specific neuronal sites. Importantly, in addition to interaction with the nuclear pore and nucleocytoplasmic transport, spastin contributes to the function of other neuronal processes (Figure 5). Spastin contains an AAA site and thus is a member of the ATPases associated with various cellular activities, which are involved in microtubule regulation, as well as proteosomes and endosome function.\textsuperscript{28,100,102} Spastin contains a microtubule interacting and trafficking protein site,\textsuperscript{100,152} and has been shown to play a role in microtubule stability and axonal transport in neurons,\textsuperscript{100} and in turn in normal synaptic growth and transmission.\textsuperscript{101} In addition, spastin has been shown to play an important role in axonal transport, which when disrupted results in neurodegeneration.\textsuperscript{28,99,100,152}

Spastin is just one example of how the anti-hnRNP A1 M9 immune response might contribute to neurodegeneration. As shown in Table 2, other genes were altered by the anti-M9 immune response.\textsuperscript{11} Future studies are needed to tease out the details of how these other groups of genes might contribute to mechanisms of neurodegeneration, including those potentially related to the progressive cognitive decline seen in MS patients,\textsuperscript{35,153,154} which has not yet been addressed in this model.
Figure 4 Heterogeneous nuclear ribonucleoprotein (hnRNP) A1 localization following TNF-α exposure in neurons. Without TNF-α exposure, hnRNP A1 is localized to nuclei (*) in dNT-2 neurons (left panels) (blue nuclear stain is diamidino-2-phenylindole; green stain is immunohistochemistry using an anti-hnRNP A1 antibody). Following exposure to TNF-α (400 ng/mL, 50 mM glutamate, 30 minutes), hnRNP A1 is also found in the cytoplasm (arrowheads) and neuronal processes (arrow) of neurons (lower right panel).

Abbreviation: TNF, tumor necrosis factor.

Figure 5 Potential contribution of the anti-heterogeneous nuclear ribonucleoprotein (hnRNP) A1 M9 immune response to neurodegeneration in immune-mediated neurological disease. Multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis patients develop antibodies to an epitope contained within the M9 region of hnRNP A1 (box). hnRNP A1 has been shown to interact molecularly with spastin RNA and protein (box and figure). The anti-M9 immune response altered spastin RNA levels, which may alter spastin function at multiple sites within neurons (blue boxes). The combination of proinflammatory cytokines and the anti-M9 immune response might contribute to neurodegeneration in immune-mediated neurological disease.

Abbreviations: TNF, tumor necrosis factor; IFN, interferon; IL, interleukin; SPG, spinal paraplegia gene.
Conclusion

Taken together, these data suggest that neurodegeneration in MS involves multiple processes. One of several possible links between autoimmunity and neurodegeneration in neurological disease has been described. The target is hnRNP A1 in neurons and the immune response is antibodies to M9, its shuttling domain required for nucleocytoplasmic transport. Anti-M9 antibodies identified integrated networks of genes that maintain neuronal and axonal function and contribute to mechanisms of neurodegeneration related to the clinical phenotype expressed by patients with immune-mediated neurological diseases, such as progressive MS and HAM/TSP. Comprehensive analyses of this type of phenotype-specific mechanism of neurodegeneration may reveal novel strategies to treat these unremitting progressive neurological diseases.

Acknowledgments

This work is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs. This study was funded by a VA Merit Review Award (to MCL) and the University of Tennessee Health Science Center Multiple Sclerosis Research Fund.

Disclosure

Drs Michael Levin and Sangmin Lee have a patent pending titled “Biomarker for neurodegeneration in neurological disease.” All other authors report no conflicts of interest in this paper.

References

Degenerative Neurological and Neuromuscular Disease downloaded from https://www.dovepress.com/ by 54.149.157.207 on 11-Oct-2016
For personal use only.
97. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in
95. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demy.
94. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple
93. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA
91. Dutta R, Trapp B. Mechanisms of neuronal dysfunction and degeneration
90. Waxman SG. Axonal conduction and injury in multiple sclerosis: the
89. Goon PK, Igakura T, Hanon E, et al. High circulating frequencies
84. Norris PJ, Hirschkorn DF, DeVita DA, Lee TH, Murphy EL. Human
81. Saxena A, Martin-Blondel G, Mars LT, Liblau RS. Role of CD8
80. Macnamara A, Rowan A, Hilburn S, et al. HLA class I binding of HBZ
78. Goon PK, Hanon E, Igakura T, et al. High frequencies of Th1-type
77. Levin et al
75. Schurmann M, Ramirez E, Gestwicki JE, et al. The roles of citrullination in
72. Doherty PM, Brown A. Cytokines in the immune response.
71. Stohlman SA, Stohlman FA. The interface between biology and medicine.
70. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
69. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
68. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
66. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
65. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
64. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
63. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
61. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
60. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
59. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
58. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
57. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
56. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
55. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
54. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
53. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
52. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
51. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
50. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
49. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
47. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
46. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
45. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
44. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
43. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
42. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
41. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
40. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
38. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
37. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
35. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
34. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
33. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
32. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
31. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
29. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
27. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
24. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
23. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
22. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
17. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
15. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
5. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
2. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
1. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.
0. Kuchroo VK, McMichael AJ, Stohlman FA. T Cells and autoimmunity.


